Intervention

Semaglutide Injection

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting2

Common conditions5

Lead sponsors shown6

Clinical trials

7 shown

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)NCT07653477 · 2026-09-07

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese AdultsNCT07465965 · 2026-03-02

The Effect of Semaglutide on the Intestinal Flora in ObesityNCT07323134 · 2026-02-01

NOT_YET_RECRUITING

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityNCT07285902 · 2025-12-25

ACTIVE_NOT_RECRUITING

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesNCT06649344 · 2024-10-31

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 DiabetesNCT06339086 · 2024-04-01

PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese AdultsNCT06863363

NOT_YET_RECRUITING

Common conditions

Obesity3 Type 2 Diabetes2 Non-diabetic Obesity1 Overweight1 Type 2 Diabetes Mellitus1

Leading sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.2 Beijing Chao Yang Hospital1 Chengdu Brilliant Pharmaceutical Co., Ltd.1 Shanghai World Leader Pharmaceutical Co., Ltd.1 Shanghai Zhongshan Hospital1 The United Bio-Technology (Hengqin) Co., Ltd.1

Trial status mix

NOT_YET_RECRUITING2

RECRUITING2

ACTIVE_NOT_RECRUITING1

COMPLETED1

UNKNOWN1

Phase mix

PHASE34

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.